36 results about "Specific antibody level" patented technology

A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.

The present invention is directed to the use of FGK-1 immunopotentiator, composed by the peptide named GK-1, characterized by the sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A and linked to the pVIII surface protein of M13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchoalveolar lavages.

The invention provides an immune enhancer for pig vaccine, and a preparation method and application thereof. The immune enhancer for pig vaccine comprises a pig gene engineering cell factor compound and a freeze-drying protective additive, wherein the pig gene engineering cell factor compound comprises the following ingredients in parts by weight: 50 to 70 parts of recombinant porcine IFN-Alpha, 15 to 25 parts of recombinant porcine IFN-Gamma and 15 to 25 parts of recombinant porcine IL-2. The immune enhancer has the following effects that after the combined use of the immune enhancer and the vaccine, the vaccine protective period specificity antibody level is improved; the antibody generating window period is shortened by 30 to 50 percent; the secretory volume of specific humoral immunity response markers 1L-4 can be improved by 1 to 5 times through being compared with that during the single use of the vaccine; the cellullar immunologic response level of the pig vaccine can be improved; the secretory volume of the cellullar immunologic response marker interferon Gamma is improved by 1 to 5 times through being compared with that during the single use of the vaccine; the safety is high; the immune enhancer can be prepared into a water soluble state; the problems that on the existing market, the vaccine immunologic adjuvant has the injection abscess, nodule and ulceration, so that the acute or chronic inflammation reaction and the like can be caused are solved.

The invention discloses a prescription, which contains aqueous extracts of shiitake mushrooms, poria cocos, zingiber officinale and dried tangerine peels and plays a role in resisting H1N1 viruses, and application thereof. The prescription is mainly made up of the shiitake mushrooms, the poria cocos, the zingiber officinale and the dried tangerine peels. Proven by antiviral tests, the prescription disclosed by the invention can be used for remarkably improving the immunologic function of H1N1 virus infected mice and improving the pneumonia pathological change degree of the H1N1 virus infected mice and can be used for remarkably improving the specific antibody level in blood serum of the H1N1 virus infected mice, remarkably lowering the content of viruses in lungs of the H1N1 virus infected mice and improving the level of lung cell factors IL-2, so that the prescription has a good H1N1 influenza virus resisting action.

This invention relates to methods that enable the detection of antibodies against a latent infection, a chronic infection, a re-infection, and / or a breakthrough infection; enable the diagnosis of a latent infection, a chronic infection, a re-infection, and / or a breakthrough infection; and increase low anti-viral antibody levels, and a kit for the detection of virus-specific antibodies expressed at low levels.

This invention relates to methods that enable the detection of antibodies against a latent infection, a chronic infection, a re-infection, and / or a breakthrough infection; enable the diagnosis of a latent infection, a chronic infection, a re-infection, and / or a breakthrough infection; and increase low anti-viral antibody levels, and a kit for the detection of virus-specific antibodies expressed at low levels.

The invention discloses beta-1,3-D-glucan modified biomimetic hollow silicon dioxide composite particles and application thereof. The composite particles are obtained by performing a coupling reactionon biomimetic hollow silicon dioxide particles and beta-1,3-D-glucan, wherein the pore diameter range of nanometer transmission pore passages of the biomimetic hollow silicon dioxide particles is 1.7-15.2nm. The composite particles have the morphologies of bacteria and the nanometer transmission pore passages with appropriate pore diameter distribution, facilitate passing of antigens and medicines with different molecular weights, have relatively high antigen loading capacity, can continuously release the antigens, can increase the antigen utilization rate, reduce the number of injections andreduce toxic and side effects of the antigens and vaccine adjuvants, and continuously provides an immunoprotective effect; the composite particles have the equivalent level of inducing antigen-specific antibodies to an aluminum adjuvant and a Freund's adjuvant, and have a wide application prospect in the biomedical field; in addition, the composite particles is simple in preparation method, low in cost, environment-friendly and low in preparation cost, and have an industrial production potential.

The invention discloses a reagent for detecting specific immune response of mycobacterium tuberculosis and use thereof. The invention discloses an immune positive reagent Rv0733 of mycobacterium tuberculosis by a gamma interferon release assay and a serum enzyme-linked immune method. The reagent comprises antigen or polypeptide and analogues thereof for detecting the specific cellular immunity of a tuberculosis sufferer and humoral immune response level. After the mice are immunized by using the reagent disclosed by the invention, the mice can generate specific cell factors such as gamma interferon and the like, and an antibody. T cells of tuberculosis patients or normal people are stimulated by using the reagent in vitro, the quantity of gamma interferon release cells is detected, or the content of gamma interferon in supernatant is cultivated, the tuberculosis patients can be distinguished from the normal people, the detection sensitivity and specificity of the tuberculosis sufferer can be improved by detecting the specific antibody level of resisting the reagent in the peripheral serum, and the clinical prognosis conditions of the tuberculosis patients can be disclosed by utilizing an Rv0733 specific immune response contrast experiment in the process of tracking treatment of the tuberculosis sufferer.

The invention relates to the technical field of biology, and discloses immunoprotection combined protein and an immune vaccine thereof. The immunoprotection combined protein includes Tm16 protein andTm-GST protein, or is Tm16 and Tm-GST fusion protein. The Tm16 protein and the Tm-GST protein are combined to be used as an immunogen immune animal; the immunoprotection effect by aiming at optimum cysticercus cerebralis is generated on animals; the synergistic effect is achieved; higher specific antibody level can be induced; a novel measure for preventing and controlling cysticercus cerebralis diseases is formed.

A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.

The invention discloses a formula, which contains a water extract of mushroom, poria cocos, ginger, and dried orange peel and can prevent H7 subtype avian influenza virus, and an application thereof. The formula is mainly composed of mushroom, poria cocos, ginger, and dried orange peel. The anti-virus experiment results show that the formula can prominently enhance the immunity of mice infected by H7 subtype avian influenza virus; the pneumonia lesion degree of the mice is improved; the specific antibody level in the serum of the mice is obviously improved; the number of viruses in the lung of the mice is prominently reduced; the lung cell factor IL-2 level is improved; and the in-vitro cell test results show that the traditional Chinese medicine composition has a prominent antivirus performance and good curative effect. The formula has a good effect on preventing H7 subtype avian influenza virus.

The invention relates to a subunit vaccine of Necroptosis bovis, which comprises three proteins, an outer membrane protein 43kDa OMP of Necroptosis bovis, a truncated protein PL-4 of necroptosis bacillus leukotoxin and a truncated protein H2 of necrolysin. The protein dosage ratio is 1:1:1. The present invention also relates to a preparation method of the above-mentioned subunit vaccine of Necroptosis bovis. The subunit vaccine of Necroptosis bovis of the present invention comprises three kinds of proteins of Necroptosis bovis outer membrane protein 43kDa OMP, Bacillus necroptosis leukotoxin truncated protein PL-4 and necrolysin truncated protein H2, combined application, after immunization The level of specific antibodies produced is high, which can well stimulate the cellular immunity and humoral immunity of mice, and effectively protect mice against the attack of necrotic bacillus.

The present invention is intended to provide a diagnostic method for paratuberculosis by which an animal infected with Mycobacterium avium subsp. Paratuberculosis can be diagnosed at a high sensitivity in the sub-clinical infection stage before the specific antibody level begins to increase and a large number of specimens can be treated. The present invention provides: a diagnostic method for paratuberculosis characterized by collecting the blood of a subject animal, adding an anti-IL-10 antibody and a Mycobacterium avium subsp. Paratuberculosis antigen to the collected blood followed by culture, and then measuring the amount of produced IFNγ in the blood; a diagnostic method for paratuberculosis characterized in that the amount of produced IFNγ in blood is measured by the IFNγ ELISA method; and a diagnostic method for mycobacterial infection characterized by collecting the blood of a subject animal, adding an anti-IL-10 antibody and a mycobacterial antigen to the collected blood followed by culture, and then measuring the amount of produced IFNγ in the blood.